Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Second Round of Dosing for Human Pilot Study #2; Set to Complete Third Study Arm in Early July
Lexaria, a global innovator in drug delivery platforms, has announced the successful completion of its second round of dosing for…